Artivion Inc
AORTHealthcare·Medical Devices·USA·Small·NYSE·Nov 11 • 8:56 AM ET
20.06-0.41 (-2.00%)
2026-11-11 15:22 CET
Market cap
998.73 USD m
Revenue, TTM
481.88 USD m
Net income, TTM
-17.57 USD m
Free cash flow, TTM
-42.63 USD m
EPS diluted, TTM
-0.36
P/E
-
Price
AORT against its 20, 50 and 200-day averages2050200miss
58.4% under 48.25 on 17 Dec 2025. Last 15 sessions, 40.6% high to low
Profile
AORT52-week range, 3% of the way up
19.1648.25
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.
| Index | RUT |
|---|---|
| Employees | 1800 |
| IPO | Feb 12, 1993 |
| Beta | 1.29 |
| ATR, 14d | 1.57 |
| Rel volume | 0.00 |
| Short float | 7.39% |
| Insider own | 5.33% |
| Inst own | 96.78% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 978.73M |
| Enterprise Value | 1.34B |
| Income | -17.57M |
| Sales | 481.88M |
| Book/sh | 9.15 |
| Cash/sh | 0.99 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | Dec 09, 2015 |
| Dividend Gr. 3/5Y | - - |
| Payout | 0.00% |
| Employees | 1800 |
| IPO | Feb 12, 1993 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | 102.56 |
| PEG | 4.76 |
| P/S | 2.03 |
| P/B | 2.19 |
| P/C | 20.22 |
| P/FCF | - |
| EV/EBITDA | 26.83 |
| EV/Sales | 2.78 |
| Quick Ratio | 2.32 |
| Current Ratio | 3.72 |
| Debt/Eq | 0.91 |
| LT Debt/Eq | 0.90 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -0.36 |
|---|---|
| EPS next Y | 0.20 |
| EPS next Q | -0.01 |
| EPS this Y | -261.21% |
| EPS next Y | 157.77% |
| EPS next 5Y | 21.54% |
| EPS past 3/5Y | - - |
| Sales past 3/5Y | 12.04% 11.75% |
| EPS Y/Y TTM | -52.01% |
| Sales Y/Y TTM | 14.01% |
| EPS Q/Q | -222.00% |
| Sales Q/Q | 9.17% |
| Earnings | Nov 05 AMC |
| EPS/Sales Surpr. | -161.01% 2.33% |
Ownership
| Insider Own | 5.33% |
|---|---|
| Insider Trans | -4.96% |
| Inst Own | 96.78% |
| Inst Trans | 3.79% |
| ROA | -1.85% |
| ROE | -3.97% |
| ROIC | -2.07% |
| Gross Margin | 59.91% |
| Oper. Margin | 4.91% |
| Profit Margin | -3.65% |
| SMA20 | -11.73% |
| SMA50 | -13.37% |
| SMA200 | -29.76% |
| Trades | - |
Technical
| Shs Outstand | 48.79M |
|---|---|
| Shs Float | 46.19M |
| Short Float | 7.39% |
| Short Ratio | 5.03 |
| Short Interest | 3.41M |
| 52W High | 48.25 -58.42% |
| 52W Low | 19.16 4.70% |
| Volatility | 10.34% 5.63% |
| ATR (14) | 1.57 |
| RSI (14) | 38.20 |
| Beta | 1.29 |
| Rel Volume | 0.00 |
| Avg Volume | 678.07K |
| Volume | 134 |
Performance
| Perf Week | -24.16% |
|---|---|
| Perf Month | -6.09% |
| Perf Quarter | -29.39% |
| Perf Half Y | -9.76% |
| Perf YTD | -56.02% |
| Perf Year | -57.19% |
| Perf 3Y | 50.49% |
| Perf 5Y | -3.93% |
| Perf 10Y | 6.14% |
| Recom | 1.00 |
| Target Price | 38.47 |
| Prev Close | 20.47 |
| Price | 20.06 |
| Change % | -2.00% |
Analyst ratings
latest 8 of 8| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Oct 20, 2026 | Initiated | JJefferies | Buy | $31 | +54.5% |
| Apr 10, 2026 | Upgrade | LLadenburg Thalmann | Neutral → Buy | $42 | +109.4% |
| Aug 13, 2025 | Downgrade | LLadenburg Thalmann | Buy → Neutral | $38.80 | +93.4% |
| Jun 17, 2025 | Initiated | CCanaccord Genuity | Buy | $35 | +74.5% |
| Oct 23, 2024 | Initiated | JJMP Securities | Mkt Outperform | $33 | +64.5% |
| Sep 27, 2022 | Reiterated | LLake Street | Buy | $32 → $28 | +39.6% |
| Aug 08, 2022 | Initiated | LLake Street | Buy | $32 | +59.5% |
| Mar 03, 2022 | Initiated | SStifel | Buy | $30 | +49.6% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| MDT | Medtronic Plc | 128.68B |
| EW | Edwards Lifesciences Corp | 58.95B |
| LMAT | Lemaitre Vascular Inc | 1.82B |
| ABT | Abbott Laboratories | 189.30B |
| LIVN | LivaNova PLC | 4.93B |
| AVR | Anteris Technologies Global Corp | 575.21M |
| ATRC | Atricure Inc | 2.86B |
| BSX | Boston Scientific Corp | 64.05B |
| BAX | Baxter International Inc | 13.63B |
| TFX | Teleflex Incorporated | 6.06B |
Insider trading
latest 14 of 100| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| GREEN ANDREW M | SVP, Regulatory and Quality | Sep 10 '26 | Sale | 24.97 | 11,480 | 286,656 | 40,160 | Sep 11 05:28 PM |
| GREEN ANDREW M | Officer | Sep 10 '26 | Proposed Sale | 24.97 | 11,480 | 286,657 | Sep 10 11:43 AM | |
| GREEN ANDREW M | SVP, Regulatory and Quality | Sep 02 '26 | Sale | 27.27 | 6,510 | 177,495 | 53,133 | Sep 04 02:15 PM |
| GREEN ANDREW M | SVP, Regulatory and Quality | Sep 03 '26 | Sale | 26.02 | 1,493 | 38,842 | 51,640 | Sep 04 02:15 PM |
| GREEN ANDREW M | Officer | Sep 03 '26 | Proposed Sale | 26.02 | 1,493 | 38,842 | Sep 03 05:16 PM | |
| GREEN ANDREW M | Officer | Sep 02 '26 | Proposed Sale | 27.27 | 6,510 | 177,498 | Sep 02 04:42 PM | |
| Stanton Marshall S. | Officer | Aug 27 '26 | Proposed Sale | 26.85 | 7,400 | 198,695 | Aug 27 02:36 PM | |
| Mackin James P | President & CEO | Aug 19 '26 | Sale | 28.95 | 70,000 | 2,026,850 | 877,275 | Aug 20 02:11 PM |
| Mackin James P | Officer | Aug 19 '26 | Proposed Sale | 29.33 | 70,000 | 2,053,100 | Aug 19 03:45 PM | |
| GREEN ANDREW M | SVP, Regulatory and Quality | Aug 14 '26 | Sale | 28.55 | 616 | 17,586 | 59,643 | Aug 17 03:18 PM |
| Berry Lance A | EVP, COO, CFO & Treasurer | Aug 14 '26 | Sale | 28.55 | 715 | 20,413 | 210,112 | Aug 17 03:17 PM |
| Berry Lance A | Officer | Aug 14 '26 | Proposed Sale | 28.55 | 715 | 20,413 | Aug 14 03:58 PM | |
| GREEN ANDREW M | Officer | Aug 14 '26 | Proposed Sale | 28.55 | 616 | 17,586 | Aug 14 03:17 PM | |
| Holloway Jean F | SVP, General Counsel | Aug 12 '26 | Sale | 28.49 | 977 | 27,835 | 184,118 | Aug 12 05:51 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IJR | iShares Core S&P Small-Cap ETF | AUM: 106.27B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| IJT | iShares S&P Small-Cap 600 Growth ETF | AUM: 7.45B |
| SPSM | State Street SPDR Portfolio S&P 600TM Small Cap ETF | AUM: 16.06B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.06B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | - |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.75B |
| SLYG | State Street SPDR S&P 600 TM Small Cap Growth ETF | AUM: 4.72B |
News
latest 14 of 206- Artivion Beats On Revenue, But A Margin Squeeze And New 2027 Perclot Headwind Drive A Steep Earnings Miss (Earnings Whispers) -20.21%
- Artivion: Q3 Earnings Snapshot (Associated Press)
- Artivion Reports Third Quarter 2026 Financial Results (PR Newswire)
- Artivion Must Prove AMDS Ramp Can Offset Nexus Costs After 15% Slide (Earnings Whispers)
- Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
- Loading…
- Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results (PR Newswire)
- Artivion rises as Jefferies initiates at buy, sees attractive entry point (Investing.com)
- Artivion Inc (AORT) (Q2 2026) Earnings Call Highlights: PMA Approval and Endospan Acquisition ... (GuruFocus.com)
- Artivion: Q2 Earnings Snapshot (Associated Press)
- Artivion Reports Second Quarter 2026 Financial Results (PR Newswire)
- Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
- Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results (PR Newswire)
- Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis (PR Newswire) -5.17%
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-11-05 | -0.160 | -0.061 | -0.160 | 123.79 | 120.98 | 8 |
| 2026Q2 | 2026-08-06 | -0.280 | 0.003 | -0.278 | 125.76 | 119.99 | 8 |
| 2026Q1 | 2026-05-07 | 0.030 | 0.026 | 0.029 | 116.34 | 115.69 | 8 |
| 2025Q4 | 2026-02-12 | 0.050 | 0.056 | 0.049 | 115.99 | 116.47 | 5 |
| 2025Q3 | 2025-11-06 | 0.130 | 0.017 | 0.133 | 113.39 | 110.44 | 7 |
| 2025Q2 | 2025-08-07 | 0.030 | -0.004 | 0.030 | 112.97 | 108.03 | 7 |
| 2025Q1 | 2025-05-05 | -0.010 | -0.121 | -0.012 | 98.98 | 94.82 | 6 |
| 2024Q4 | 2025-02-24 | -0.390 | -0.065 | -0.393 | 97.31 | 100.89 | 6 |
| 2024Q3 | 2024-11-07 | -0.050 | -0.063 | -0.055 | 95.78 | 94.76 | 6 |
| 2024Q2 | 2024-08-08 | -0.050 | -0.090 | -0.051 | 98.02 | 97.60 | 5 |
| 2024Q1 | 2024-05-06 | 0.180 | -0.120 | 0.176 | 97.43 | 92.06 | 5 |
| 2023Q4 | 2024-02-15 | -0.100 | -0.086 | -0.097 | 93.67 | 89.28 | 5 |
| 2023Q3 | 2023-11-02 | -0.240 | -0.062 | -0.239 | 87.85 | 84.32 | 5 |
| 2023Q2 | 2023-08-03 | -0.080 | -0.055 | -0.083 | 89.25 | 84.24 | 4 |
| 2023Q1 | 2023-05-04 | -0.330 | -0.112 | -0.333 | 83.23 | 80.35 | 5 |
| 2022Q4 | 2023-02-16 | 0.050 | -0.124 | 0.053 | 79.40 | 79.85 | 5 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | 0.050 | 0.090 | 0.045 | 276.22 | 277.35 |
| 2020FY | -0.440 | -0.398 | -0.438 | 253.23 | 251.78 |
| 2021FY | -0.380 | 0.067 | -0.378 | 298.84 | 297.24 |
| 2022FY | -0.480 | -0.656 | -0.477 | 313.79 | 314.34 |
| 2023FY | -0.750 | -0.742 | -0.750 | 354 | 349.64 |
| 2024FY | -0.320 | 0.008 | -0.320 | 388.54 | 392.06 |
| 2025FY | 0.210 | 0.214 | 0.210 | 441.33 | 441.77 |
| 2026FY | - | -0.339 | - | - | 488.89 |
| 2027FY | - | 0.196 | - | - | 534.53 |
| 2028FY | - | 0.377 | - | - | 593.85 |
| 2029FY | - | 0.970 | - | - | 670.5 |
| 2030FY | - | 1.590 | - | - | 756.4 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-11-06 | 9 | 0 | 7 | 124.84 | 122.1 | 131.3 |
| 2026Q4 | S | 2026-11-05 | 9 | 0 | 0 | 128.72 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-10-31 | 9 | 0 | 0 | 128.72 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-10-21 | 9 | 1 | 0 | 128.72 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-10-19 | 9 | 3 | 1 | 128.72 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-10-16 | 9 | 3 | 1 | 128.72 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-08-17 | 8 | 3 | 1 | 128.68 | 126.5 | 131.3 |
| 2026Q4 | S | 2026-08-07 | 8 | 2 | 1 | 128.5 | 126.5 | 129.8 |
| 2026Q4 | S | 2026-08-02 | 8 | 0 | 0 | 128.4 | 126.5 | 130.1 |
| 2026Q4 | S | 2026-07-22 | 8 | 0 | 1 | 128.4 | 126.5 | 130.1 |
| 2026Q4 | S | 2026-07-17 | 8 | 2 | 5 | 128.4 | 126.5 | 130.1 |
| 2026Q4 | S | 2026-06-29 | 8 | 2 | 5 | 128.4 | 126.5 | 130.1 |
| 2026Q4 | S | 2026-06-26 | 8 | 2 | 5 | 128.43 | 126.5 | 130.3 |
| 2026Q4 | S | 2026-06-22 | 8 | 2 | 5 | 128.44 | 126.5 | 130.3 |
Estimate history
| EPS, annual | 0.11 | -0.077 | 0.045 | -0.438 | -0.378 | -0.477 | -0.75 | -0.32 | 0.207 | -0.3631 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -0.055 | -0.393 | -0.012 | 0.03 | 0.133 | 0.049 | 0.029 | -0.278 | -0.163 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Sales, annual | 189.702 | 262.841 | 276.222 | 253.227 | 298.836 | 313.789 | 354.004 | 388.537 | 441.33 | 481.88 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 95.779 | 97.308 | 98.978 | 112.972 | 113.388 | 115.992 | 116.337 | 125.757 | 123.79 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Shares, annual | 36.231 | 36.979 | 37.534 | 38.907 | 39.91 | 40.343 | 41.082 | 41.945 | 47.843 | 48.79 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 41.905 | 41.945 | 42.703 | 47.105 | 47.375 | 47.843 | 48.496 | 48.692 | 48.79 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 481.88 | 441.33 | 388.54 | 354.00 | 313.79 | 298.84 | 253.23 | 276.22 | 262.84 |
| Cost of Goods Sold Incl. D&A | 193.18 | 170.88 | 155.61 | 140.03 | 126.58 | 118.14 | 99.21 | 104.06 | 100.65 |
| Gross Profit | 288.69 | 270.45 | 232.93 | 213.98 | 187.21 | 180.69 | 154.02 | 172.16 | 162.19 |
| Selling, General and Administrative Excl. Other | 265.04 | 236.27 | 205.44 | 199.19 | 172.23 | 174.34 | 151.48 | 152.80 | 144.48 |
| Research and Development | 36.83 | 30.99 | 28.45 | 28.71 | 38.88 | 35.55 | 24.21 | 22.96 | 23.10 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 23.65 | 34.19 | 27.49 | 14.79 | 14.98 | 6.35 | 2.54 | 19.36 | 17.71 |
| Interest Expense | 26.67 | 26.68 | 34.37 | 25.38 | 17.84 | 16.52 | 16.82 | 15.01 | 15.79 |
| Unusual Expense | 17.20 | 12.66 | -2.44 | 28.88 | 9.47 | 15.33 | 5.84 | 3.10 | 8.40 |
| Net Income Before Taxes | -10.74 | 14.78 | -7.51 | -21.59 | -14.98 | -14.83 | -17.17 | 1.64 | -6.39 |
| Income Taxes | 6.85 | 5.01 | 5.84 | 9.10 | 4.21 | 0.01 | -0.49 | -0.08 | -3.55 |
| Consolidated Net Income | -17.57 | 9.76 | -13.34 | -30.57 | -19.09 | -14.74 | -16.57 | 1.71 | -2.81 |
| Net Income From Continuing Operations | -17.57 | 9.76 | -13.34 | -30.57 | -19.09 | -14.74 | -16.57 | 1.71 | -2.81 |
| Net Income | -17.57 | 9.76 | -13.34 | -30.57 | -19.09 | -14.74 | -16.57 | 1.71 | -2.81 |
| EPS (Recurring) | -0.11 | 0.39 | -0.36 | -0.26 | -0.31 | -0.10 | -0.33 | 0.10 | 0.08 |
| EPS (Basic, Before Extraordinaries) | -0.36 | 0.22 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.08 |
| EPS (Diluted) | -0.36 | 0.21 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.08 |
| EBITDA | 49.84 | 56.64 | 51.69 | 37.86 | 37.43 | 30.33 | 30.40 | 42.69 | 35.81 |
| Non-Operating Income (Expense) | 9.47 | 19.93 | -3.08 | 17.89 | -2.65 | 10.67 | 2.94 | 0.39 | 0.09 |
| Other After Tax Adjustments | 0.02 | -0.01 | 0.02 | 0.12 | 0.10 | 0.09 | 0.11 | -0.01 | 0.03 |
| Stock Option Compensation Expense | 20.94 | 19.26 | 11.82 | 11.97 | 10.22 | 8.23 | 5.48 | 5.44 | 5.38 |
| Price To Earnings Ratio | - | - | - | - | - | - | - | 607.40 | - |
| Price To Sales Ratio | 2.31 | 4.87 | 3.07 | 2.06 | 1.55 | 2.65 | 3.53 | 3.71 | 3.93 |
| Gross Margin | 59.91 | 61.28 | 59.95 | 60.45 | 59.66 | 60.47 | 60.82 | 62.33 | 61.71 |
| Operating Margin | 4.91 | 7.75 | 7.07 | 4.18 | 4.78 | 2.12 | 1.00 | 7.01 | 6.74 |
| Net Margin | -3.65 | 2.21 | -3.43 | -8.63 | -6.08 | -4.93 | -6.54 | 0.62 | -1.07 |
| Shares Outstanding | 48.79 | 47.84 | 41.95 | 41.08 | 40.34 | 39.91 | 38.91 | 37.53 | 36.98 |
| Market Capitalization | 998.73 | 998.73 | 1,198.49 | 733.95 | 488.79 | 800.36 | 917.42 | 1,015.98 | 1,049.15 |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 123.79 | 125.76 | 116.34 | 115.99 | 113.39 | 112.97 | 98.98 | 97.31 |
| Cost of Goods Sold Incl. D&A | 52.58 | 49.47 | 44.80 | 46.33 | 42.47 | 43.29 | 38.79 | 40.01 |
| Gross Profit | 71.21 | 76.29 | 71.54 | 69.66 | 70.92 | 69.69 | 60.19 | 57.30 |
| Selling, General and Administrative Excl. Other | 67.16 | 76.66 | 64.05 | 57.18 | 59.28 | 58.70 | 55.24 | 53.44 |
| Research and Development | 9.81 | 9.05 | 8.84 | 9.12 | 8.08 | 7.06 | 6.73 | 7.40 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 4.05 | -0.36 | 7.49 | 12.48 | 11.64 | 10.98 | 4.95 | 3.86 |
| Interest Expense | 8.52 | 7.25 | 5.37 | 5.53 | 6.12 | 7.27 | 7.66 | 9.74 |
| Unusual Expense | 1.10 | 8.00 | 1.70 | 6.40 | 2.70 | 5.76 | 3.10 | 1.19 |
| Net Income Before Taxes | -5.92 | -11.70 | 0.34 | 6.54 | 7.06 | 3.48 | -2.29 | -16.60 |
| Income Taxes | 2.01 | 1.81 | -1.08 | 4.11 | 0.55 | 2.14 | -1.79 | -0.12 |
| Consolidated Net Income | -7.92 | -13.49 | 1.42 | 2.42 | 6.50 | 1.34 | -0.50 | -16.45 |
| Net Income From Continuing Operations | -7.92 | -13.49 | 1.42 | 2.42 | 6.50 | 1.34 | -0.50 | -16.45 |
| Net Income | -7.92 | -13.49 | 1.42 | 2.42 | 6.50 | 1.34 | -0.50 | -16.45 |
| EPS (Recurring) | -0.15 | -0.16 | 0.05 | 0.14 | 0.17 | 0.12 | 0.04 | -0.37 |
| EPS (Basic, Before Extraordinaries) | -0.16 | -0.28 | 0.03 | 0.05 | 0.14 | 0.03 | -0.01 | -0.39 |
| EPS (Diluted) | -0.16 | -0.28 | 0.03 | 0.05 | 0.13 | 0.03 | -0.01 | -0.39 |
| EBITDA | 11.39 | 6.38 | 13.83 | 18.24 | 17.35 | 16.52 | 10.39 | 10.15 |
| Non-Operating Income (Expense) | -0.35 | 3.92 | -0.08 | 5.99 | 4.24 | 5.53 | 3.52 | -9.53 |
| Other After Tax Adjustments | 0.01 | 0.02 | -0.00 | -0.00 | -0.01 | -0.00 | 0.00 | 0.03 |
| Stock Option Compensation Expense | 4.92 | 6.45 | 6.35 | 3.23 | 4.85 | 4.84 | 6.36 | 2.17 |
| Price To Earnings Ratio | - | 93.59 | 183.38 | - | - | - | - | - |
| Price To Sales Ratio | 2.31 | 2.31 | 3.97 | 5.13 | 4.89 | 3.48 | 2.66 | 3.08 |
| Gross Margin | 57.52 | 60.67 | 61.49 | 60.06 | 62.55 | 61.68 | 60.81 | 58.88 |
| Operating Margin | 3.27 | -0.29 | 6.44 | 10.76 | 10.26 | 9.72 | 5.00 | 3.97 |
| Net Margin | -6.39 | -10.73 | 1.22 | 2.09 | 5.73 | 1.19 | -0.51 | -16.91 |
| Shares Outstanding | 48.79 | 48.69 | 48.50 | 47.84 | 47.38 | 47.10 | 42.70 | 41.95 |
| Market Capitalization | 998.73 | 1,090.77 | 1,753.51 | 2,160.77 | 1,997.76 | 1,328.06 | 1,033.54 | 1,198.49 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 64.91 | 53.46 | 58.94 | 39.35 | 55.01 | 61.96 | 34.29 | 42.24 | 40.75 |
| Short Term Receivables | 103.68 | 85.89 | 74.14 | 69.58 | 58.10 | 48.75 | 55.86 | 51.43 | 51.44 |
| Inventories | 92.43 | 79.77 | 81.98 | 74.48 | 76.97 | 73.04 | 53.07 | 45.48 | 46.68 |
| Other Current Assets | 42.54 | 19.26 | 15.81 | 17.55 | 14.75 | 14.29 | 11.61 | 6.85 | 4.73 |
| Total Current Assets | 303.55 | 238.38 | 230.86 | 200.96 | 204.83 | 198.04 | 154.84 | 145.99 | 143.61 |
| Net Property, Plant & Equipment | 99.69 | 76.13 | 82.18 | 80.53 | 83.23 | 51.65 | 54.14 | 31.03 | 33.58 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 410.59 | 397.34 | 419.57 | 426.28 | 451.50 | 487.12 | 344.43 | 348.86 | 367.74 |
| Deferred Tax Assets | 1.20 | 1.07 | 1.09 | 1.31 | 2.36 | 1.45 | 5.48 | 4.11 | 1.61 |
| Other Assets | 69.77 | 76.18 | 58.70 | 53.71 | 51.13 | 51.15 | 46.76 | 41.10 | 43.16 |
| Total Assets | 884.80 | 789.10 | 792.40 | 762.80 | 793.05 | 789.40 | 605.65 | 571.09 | 589.69 |
| Short Term Debt Incl. Current Port. of LT Debt | 6.28 | 5.29 | 6.43 | 5.43 | 5.31 | 7.57 | 7.25 | 1.89 | 1.30 |
| Accounts Payable | 16.04 | 17.97 | 13.32 | 12.00 | 10.39 | 9.62 | 9.80 | 7.55 | 9.77 |
| Income Tax Payable | 7.49 | 2.93 | 3.84 | 2.63 | 3.63 | 2.81 | 2.98 | 2.25 | 4.02 |
| Other Current Liabilities | 71.75 | 40.63 | 34.28 | 29.61 | 25.62 | 40.47 | 25.17 | 22.84 | 27.86 |
| Total Current Liabilities | 101.56 | 66.82 | 57.86 | 49.67 | 44.95 | 60.47 | 45.20 | 34.52 | 42.94 |
| Long Term Debt | 252.24 | 356.97 | 352.91 | 351.40 | 356.74 | 309.80 | 237.90 | 221.66 | 225.09 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 24.31 | 20.18 | 21.85 | 24.50 | 28.80 | 34.71 | 25.84 | 27.27 | 30.43 |
| Other Liabilities | 58.46 | 68.92 | 77.99 | 52.90 | 61.84 | 55.71 | 11.02 | 12.58 | 14.17 |
| Total Liabilities | 436.56 | 512.90 | 510.62 | 478.47 | 492.32 | 460.69 | 319.96 | 296.02 | 312.63 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 448.23 | 276.20 | 281.78 | 284.33 | 300.73 | 328.71 | 285.70 | 275.07 | 277.06 |
| Total Shareholders Equity | 448.23 | 276.20 | 281.78 | 284.33 | 300.73 | 328.71 | 285.70 | 275.07 | 277.06 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 448.23 | 276.20 | 281.78 | 284.33 | 300.73 | 328.71 | 285.70 | 275.07 | 277.06 |
| Total Liabilities & Stockholders Equity | 884.80 | 789.10 | 792.40 | 762.80 | 793.05 | 789.40 | 605.65 | 571.09 | 589.69 |
| Book Value Per Share | 9.37 | 6.58 | 6.86 | 7.05 | 7.54 | 8.45 | 7.61 | 7.44 | 7.65 |
| Tangible Book Value Per Share | 0.79 | -2.89 | -3.35 | -3.52 | -3.78 | -4.07 | -1.56 | -2.00 | -2.50 |
| Full-Time Employees | 1,800 | 1,600 | 1,500 | 1,300 | 1,300 | 1,200 | 1,200 | 1,100 | 1,000 |
| Price to Book Ratio | 2.24 | 3.93 | 2.70 | 1.92 | 2.70 | 2.79 | 3.56 | 3.82 | 2.87 |
| Return on Assets | 1.17 | -1.69 | -3.93 | -2.45 | -1.86 | -2.38 | 0.29 | -0.48 | 0.80 |
| Return on Equity | 2.69 | -4.78 | -10.80 | -6.53 | -4.68 | -5.39 | 0.61 | -1.02 | 1.50 |
| Return on Invested Capital | 1.39 | -2.11 | -4.82 | -3.00 | -2.24 | -2.60 | 0.33 | -0.57 | 0.73 |
| Quick Ratio | 2.08 | 2.37 | 2.57 | 2.55 | 2.84 | 2.07 | 2.25 | 2.91 | 2.26 |
| Current Ratio | 2.99 | 3.57 | 3.99 | 4.05 | 4.56 | 3.28 | 3.43 | 4.23 | 3.34 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.59 | 9.77 | -13.36 | -30.69 | -19.19 | -14.83 | -16.68 | 1.72 | -2.84 |
| Depreciation | 26.19 | 22.46 | 24.20 | 23.08 | 22.44 | 23.98 | 27.86 | 23.33 | 18.09 |
| Other Funds (Non Cash) | 51.57 | 29.78 | 30.14 | 43.77 | 19.25 | 23.75 | 23.61 | 12.47 | 9.12 |
| Funds from Operations | 60.85 | 62.04 | 39.48 | 34.77 | 20.78 | 28.43 | 39.06 | 35.21 | 19.89 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -44.21 | -22.16 | -17.24 | -16.19 | -25.94 | -33.23 | -26.70 | -19.38 | -10.01 |
| Cash from Operating Activities | 16.64 | 39.88 | 22.24 | 18.58 | -5.15 | -4.80 | 12.37 | 15.83 | 9.88 |
| Capital Expenditures | -59.27 | -39.04 | -11.19 | -7.43 | -10.71 | -13.09 | -7.33 | -8.07 | -5.79 |
| Net Assets From Acquisitions | -116.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -59.12 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 5.00 | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | -12.50 | -8.00 | -17.00 | -7.32 | 0.00 | -0.25 | -6.68 | -15.87 | -0.93 |
| Other Sources | 0.00 | 0.00 | 0.00 | 14.25 | 0.00 | 19.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -183.43 | -42.04 | -28.19 | -0.50 | -10.71 | 5.66 | -73.13 | -23.94 | -6.71 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.58 | 13.07 | 5.73 | 3.40 | 1.57 | 1.84 | 0.44 | 2.02 | 1.75 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | -0.56 | -1.79 | -1.91 | -2.00 | -2.74 | -2.10 |
| Sale of Common Pref Stock | 7.58 | 13.07 | 5.73 | 3.96 | 3.37 | 3.76 | 2.43 | 4.76 | 3.85 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 148.82 | 0.66 | -2.90 | -1.75 | -2.75 | -3.08 | 91.01 | -2.78 | -3.41 |
| Change in Long Term Debt | 148.87 | -0.21 | -1.88 | -2.77 | -2.75 | -3.08 | 91.01 | -2.78 | -3.41 |
| Issuance of Long Term Debt | 148.88 | 0.00 | 209.96 | 0.00 | 0.00 | 0.00 | 126.35 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.00 | -0.21 | -211.83 | -2.77 | -2.75 | -3.08 | -35.35 | -2.78 | -3.41 |
| Net Financing Active Other Cash Flow | -12.41 | -0.70 | -0.62 | -0.54 | -0.46 | -8.76 | 2.16 | -0.73 | -0.90 |
| Other Financing Activities Uses | -12.51 | -0.70 | -0.62 | -0.54 | -0.46 | -8.76 | -0.65 | -0.73 | -0.90 |
| Cash from Financing Activities | 142.25 | 11.28 | 2.20 | 1.11 | -1.64 | -10.00 | 93.61 | -1.49 | -2.56 |
| Exchange Rate Effect | -0.49 | 2.32 | -1.73 | 0.40 | 1.85 | 2.20 | -5.18 | 1.67 | 0.88 |
| Net Change in Cash | -25.03 | 11.45 | -5.48 | 19.59 | -15.66 | -6.95 | 27.66 | -7.94 | 1.48 |
| Free Cash Flow | -42.63 | 0.84 | 11.05 | 11.15 | -14.17 | -17.89 | 5.04 | 7.75 | 4.09 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | - | 2,563.84 | 107.85 | 65.36 | - | - | 177.33 | 132.25 | 252.35 |
| Deferred Taxes & Investment Tax Credit | - | 0.04 | -1.51 | -1.39 | -1.72 | -4.47 | 4.28 | -2.31 | -4.49 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 48.40 | 77.32 | 55.76 | 64.91 | 73.43 | 53.48 |
| Short Term Receivables | 106.37 | 110.76 | 105.62 | 103.68 | 97.37 | 101.25 |
| Inventories | 107.05 | 103.36 | 98.00 | 92.43 | 90.55 | 86.72 |
| Other Current Assets | 23.26 | 26.57 | 44.73 | 42.54 | 22.45 | 24.55 |
| Total Current Assets | 285.08 | 318.01 | 304.10 | 303.55 | 283.79 | 266.00 |
| Net Property, Plant & Equipment | 117.27 | 110.28 | 102.30 | 99.69 | 79.59 | 79.78 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 566.87 | 573.83 | 406.55 | 410.59 | 410.84 | 412.24 |
| Deferred Tax Assets | 1.27 | 1.22 | 1.14 | 1.20 | 0.60 | 0.69 |
| Other Assets | 71.60 | 68.59 | 69.07 | 69.77 | 82.84 | 79.67 |
| Total Assets | 1,042.09 | 1,071.93 | 883.16 | 884.80 | 857.66 | 838.39 |
| Short Term Debt Incl. Current Port. of LT Debt | 5.95 | 5.92 | 5.53 | 6.28 | 5.80 | 5.74 |
| Accounts Payable | 17.63 | 20.87 | 18.34 | 16.04 | 16.50 | 19.43 |
| Income Tax Payable | 4.09 | 5.58 | 7.13 | 7.49 | 2.07 | 2.85 |
| Other Current Liabilities | 48.98 | 74.56 | 61.70 | 71.75 | 61.47 | 38.66 |
| Total Current Liabilities | 76.66 | 106.93 | 92.70 | 101.56 | 85.84 | 66.67 |
| Long Term Debt | 401.08 | 402.05 | 252.63 | 252.24 | 256.19 | 258.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 24.72 | 25.88 | 27.64 | 24.31 | 21.93 | 23.45 |
| Other Liabilities | 93.23 | 91.48 | 59.73 | 58.46 | 55.01 | 70.36 |
| Total Liabilities | 595.69 | 626.35 | 432.69 | 436.56 | 418.97 | 418.49 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 446.40 | 445.58 | 450.47 | 448.23 | 438.69 | 419.90 |
| Total Shareholders Equity | 446.40 | 445.58 | 450.47 | 448.23 | 438.69 | 419.90 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 446.40 | 445.58 | 450.47 | 448.23 | 438.69 | 419.90 |
| Total Liabilities & Stockholders Equity | 1,042.09 | 1,071.93 | 883.16 | 884.80 | 857.66 | 838.39 |
| Book Value Per Share | 9.15 | 9.15 | 9.29 | 9.37 | 9.26 | 8.91 |
| Tangible Book Value Per Share | -2.47 | -2.63 | 0.91 | 0.79 | 0.59 | 0.16 |
| Full-Time Employees | - | - | - | 1,800 | - | - |
| Price to Book Ratio | 2.24 | 2.42 | 3.91 | 4.93 | 4.75 | 4.51 |
| Return on Assets | -1.85 | -0.33 | 1.39 | 1.17 | -1.10 | -2.20 |
| Return on Equity | -3.97 | -0.73 | 3.14 | 2.69 | -2.45 | -5.01 |
| Return on Invested Capital | -0.93 | -1.59 | 0.20 | 0.35 | 0.93 | 0.20 |
| Quick Ratio | 2.32 | 2.01 | 2.22 | 2.08 | 2.25 | 2.69 |
| Current Ratio | 3.72 | 2.97 | 3.28 | 2.99 | 3.31 | 3.99 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | -7.93 | -13.51 | 1.42 | 2.43 | 6.50 | 1.34 |
| Depreciation | 7.34 | 6.75 | 6.34 | 5.76 | 5.72 | 5.54 |
| Other Funds (Non Cash) | 13.51 | 15.63 | 13.05 | 9.38 | 6.31 | 9.22 |
| Funds from Operations | 13.51 | 7.97 | 20.28 | 19.09 | 17.27 | 15.88 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -18.07 | -9.23 | -19.13 | 2.22 | 3.24 | -0.87 |
| Cash from Operating Activities | -4.56 | -1.27 | 1.15 | 21.31 | 20.51 | 15.01 |
| Capital Expenditures | -13.01 | -10.75 | -8.00 | -27.51 | -4.61 | -3.29 |
| Net Assets From Acquisitions | 0.00 | -116.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | -2.00 | -2.50 | -8.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -13.01 | -129.41 | -10.50 | -30.51 | -4.61 | -3.29 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.50 | 1.38 | 1.25 | 3.46 | 5.15 | 0.28 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.50 | 1.38 | 1.25 | 3.46 | 5.15 | 0.28 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.87 | 148.01 | -0.58 | 2.26 | -0.91 | -0.62 |
| Change in Long Term Debt | 0.00 | 148.88 | 0.00 | -0.00 | -0.07 | -0.07 |
| Issuance of Long Term Debt | 0.00 | 148.88 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | -0.00 | -0.07 | -0.07 |
| Net Financing Active Other Cash Flow | -11.91 | 3.00 | -0.21 | -3.29 | -0.17 | 2.94 |
| Other Financing Activities Uses | -11.91 | -0.22 | -0.21 | -0.17 | -0.17 | -0.17 |
| Cash from Financing Activities | -11.28 | 152.39 | 0.46 | 0.68 | 4.07 | 2.60 |
| Exchange Rate Effect | -0.07 | -0.16 | -0.26 | -0.00 | -0.02 | 1.46 |
| Net Change in Cash | -28.92 | 21.55 | -9.14 | -8.52 | 19.95 | 15.78 |
| Free Cash Flow | -17.57 | -12.01 | -6.85 | -6.20 | 15.90 | 11.72 |
| Price to Free Cash Flow | - | - | 124.90 | 2,696.43 | 131.12 | 184.16 |
Revenue breakdown
| Aortic Stent Grafts | 2024: 123.08M 2025: 159.37M |
|---|---|
| On X | 2024: 83.98M 2025: 101.74M |
| Other Products | 2024: 9.27M 2025: 8.11M |
| Preservation Services | 2024: 98.31M 2025: 95.51M |
| Surgical Sealants | 2024: 73.90M 2025: 76.60M |
| Non-US | 2024: 198.54M 2025: 227.26M |
| United States | 2024: 189.99M 2025: 214.08M |
| Asia Pacific | 2024: 37.20M 2025: 44.25M |
| Europe, the Middle East, and Africa Segments | 2024: 131.52M 2025: 151.37M |
| Latin America | 2024: 21.88M 2025: 23.97M |
| North America | 2024: 197.94M 2025: 221.74M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 7.39% | 3.4M | 46.2M | 624.81K |
| 2026-10-15 | 8.09% | 3.7M | 46.2M | 640.21K |
| 2026-09-30 | 7.85% | 3.6M | 46.2M | 647.27K |
| 2026-09-15 | 7.11% | 3.3M | 46.2M | 713.89K |
| 2026-08-31 | 6.34% | 2.9M | 46.2M | 747.50K |
| 2026-08-14 | 5.95% | 2.7M | 46.1M | 754.48K |
| 2026-07-31 | 5.87% | 2.7M | 46.1M | 803.76K |
| 2026-07-15 | 5.42% | 2.5M | 46.1M | 760.62K |
| 2026-06-30 | 4.73% | 2.2M | 46.1M | 751.37K |
| 2026-06-15 | 4.10% | 1.9M | 46.1M | 637.56K |
| 2026-05-29 | 4.16% | 1.9M | 46.1M | 569.15K |
| 2026-05-15 | 4.21% | 1.9M | 46.1M | 553.38K |
| 2026-04-30 | 4.15% | 1.9M | 46.2M | 439.03K |
| 2026-04-15 | 4.20% | 1.9M | 46.2M | 442.79K |
| 2026-03-31 | 3.65% | 1.7M | 45.7M | 404.85K |
| 2026-03-13 | 3.67% | 1.7M | 45.7M | 397.62K |
| 2026-02-27 | 3.45% | 1.6M | 45.7M | 389.69K |
| 2026-02-13 | 3.04% | 1.4M | 45.7M | 361.89K |
| 2026-01-30 | 3.63% | 1.6M | 45.2M | 363.80K |
| 2026-01-15 | 3.53% | 1.6M | 45.2M | 366.36K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 12.50 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| call | 15.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| call | 17.50 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| call | 20.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| call | 22.50 | 0.00 | 0.00 | 4.00 | - | 4.00 | 0.00 | - | - | - |
| call | 25.00 | 0.00 | 0.00 | 0.05 | - | 22.00 | 0.00 | - | - | - |
| call | 30.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| call | 35.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| put | 12.50 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| put | 15.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| put | 17.50 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| put | 20.00 | 0.00 | 0.00 | 0.40 | - | 1.00 | 0.00 | - | - | - |
| put | 22.50 | 0.00 | 0.00 | 1.60 | - | 2.00 | 0.00 | - | - | - |
| put | 25.00 | 0.00 | 0.00 | 2.11 | - | 1.00 | 0.00 | - | - | - |
| put | 30.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
| put | 35.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-10-27 | SCHEDULE 13G/A | SEC | ||
| 2026-09-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-10 | SEC |
| 2026-09-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-02 | SEC |
| 2026-09-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-02 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-27 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-19 | SEC |
| 2026-08-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-08-06 | SCHEDULE 13G/A | SEC | ||
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-08 | 3 | Initial statement of beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-02 | SEC |
| 2026-05-21 | SD | Specialized Disclosure Report | SEC | |
| 2026-05-20 | 4/A | 2026-05-18 | SEC | |
| 2026-05-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
| 2026-05-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
| 2026-05-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
| 2026-05-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
| 2026-05-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 502.99K | 3 |
| 2026-08 | 0 | 0 | 2.09M | 4 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 910.74K | 1 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 2.72M | 13 |
| 2026-02 | 0 | 0 | 2.25M | 12 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 3.57M | 5 |
| 2025-11 | 0 | 0 | 8.67M | 19 |
Institutional holders
| Manager | % owned |
|---|---|
| - | |
Funds
| Fund | % owned |
|---|---|
| iShares Core S&P Small-Cap ETF | 5.30% |
| Nomura Small Cap Core Fund | 3.89% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.01% |
| iShares Russell 2000 ETF | 2.44% |
| CONESTOGA SMALL CAP FUND | 1.98% |
| Fidelity Small Cap Value Fund | 1.26% |
| Nomura Small Cap Growth Fund | 1.13% |
| Fidelity Small Cap Growth Fund | 1.10% |
| Fidelity Stock Selector Small Cap Fund | 1.05% |
| Fidelity Small Cap Index Fund | 1.03% |
OakChart. AORT. Cached 15 minutes.